Who are Supportive care+Ripertamab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): imatinib (IM), DCC-2618, Nilotinib, Imatinib, Imatinib (Glivec), Inlyta, Sequential Icotinib Plus Chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/supportive-care-ripertamab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Supportive care+Ripertamab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Supportive care+Ripertamab (Supportive care+Ripertamab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tyrosine kinase inhibitor. Area: Oncology.

phase 3 tyrosine kinase inhibitor KIT, PDGFRA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Supportive care+Ripertamab (Supportive care+Ripertamab) — Air Force Military Medical University, China. Ripretinib targets and inhibits the activity of KIT and PDGFRA kinases, which are involved in the growth and spread of cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Supportive care+Ripertamab TARGET	Supportive care+Ripertamab	Air Force Military Medical University, China	phase 3	tyrosine kinase inhibitor	KIT, PDGFRA
imatinib (IM)	imatinib (IM)	First Affiliated Hospital, Sun Yat-Sen University	marketed	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA
DCC-2618	DCC-2618	Deciphera Pharmaceuticals, LLC	phase 3	Tyrosine kinase inhibitor	KIT, PDGFRA
Nilotinib, Imatinib	Nilotinib, Imatinib	Seoul St. Mary's Hospital	phase 3	Tyrosine kinase inhibitor (TKI)	BCR-ABL, KIT, PDGFRA
Imatinib (Glivec)	Imatinib (Glivec)	Dermatologic Cooperative Oncology Group	phase 3	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Sequential Icotinib Plus Chemotherapy	Sequential Icotinib Plus Chemotherapy	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tyrosine kinase inhibitor class)

Centre Leon Berard · 2 drugs in this class
Akeso · 1 drug in this class
Astex Pharmaceuticals, Inc. · 1 drug in this class
Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Jiangsu ShengDiYa Medicine Co., Ltd. · 1 drug in this class
Nanjing Leads Biolabs Co.,Ltd · 1 drug in this class
Ocular Therapeutix, Inc. · 1 drug in this class
Peking University Cancer Hospital & Institute · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Supportive care+Ripertamab — Competitive Intelligence Brief. https://druglandscape.com/ci/supportive-care-ripertamab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing